Non-Viral Drug Delivery Systems Market

Table of Contents

SECTION I: REPORT OVERVIEW

1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis

2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis

2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources

2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach

2.4.2.2. Advantages of Primary Research\

2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions

2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers

2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity

2.4.3. Analytical Tools and Databases

2.5. Robust Quality Control

3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach

3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)

3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis

3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact

3.6. Limitations

4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates

4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations
4.2.2.3. Impact of Currency Fluctuations on the Industry

4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk

4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt

4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on Market Evolution

4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on Market
4.2.6.2. Strategies for Managing Interest Rate Risk

4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation

4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market

4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War

4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies

4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product (GDP)
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross-Border Dynamics

4.3. Conclusion

SECTION II: QUALITATIVE INSIGHTS

5. EXECUTIVE SUMMARY

6. INTRODUCTION
6.1. Chapter Overview
6.2. Need for Targeted Drug Delivery

6.3. Advanced Approaches for Delivery of Drug Payloads
6.3.1. Nanoparticular Delivery Systems
6.3.1.1. Liposomes
6.3.1.2. Nanoparticles / Microparticles
6.3.1.3. Poly-ethylene Glycol (PEG)
6.3.1.4. Cell Penetrating Peptides (CPPs)

6.3.2. Other Drug Delivery Technologies

6.4. Future Perspectives

SECTION III: MARKET OVERVIEW

7. TECHNOLOGY LANDSCAPE
7.1. Chapter Overview
7.2. Non-Viral Drug Delivery: Overall Systems / Technology Landscape
7.2.1. Analysis by Type of Molecule Delivered
7.2.2. Analysis by Type of Biologic Delivered
7.2.3. Analysis by Type of Drug Interaction
7.2.4. Analysis by Type of Vehicle Used
7.2.5. Analysis by Most Active Players

7.3. Non-Viral Drug Delivery: Overall Systems / Technology Providers Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
7.3.4. Analysis by Company Size and Location of Headquarters
7.3.5. Analysis by Company Size and Type of Molecule Delivered

8. TECHNOLOGY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology

8.4. Non-Viral Drug Delivery Systems / Technologies: Technology Competitiveness Analysis
8.4.1. Non-Viral Drug Delivery Systems / Technologies of Players based in North America
8.4.2. Non-Viral Drug Delivery Systems / Technologies of Players based in Europe
8.4.3. Non-Viral Drug Delivery Systems / Technologies of Players based in Asia-Pacific and Rest of the World

SECTION IV: COMPANY PROFILES

9. COMPANY PROFILES
9.1. Chapter Overview
9.2. Arcturus Therapeutics
9.2.1. Company Overview
9.2.2. Technology Portfolio
9.2.3. Recent Developments and Future Outlook

9.3. Bio-Path Holdings
9.4. CureVac
9.5. Entos Pharmaceuticals
9.6. etherna
9.7. Matinas Biopharma
9.8. MDimune
9.9. PCI Biotech

SECTION V: MARKET TRENDS

10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology

10.3. Non-Viral Drug Delivery Systems / Technologies: Patent Analysis
10.3.1. Analysis by Type of Patent
10.3.2. Analysis by Publication Year
10.3.3. Analysis by Application Year
10.3.4. Analysis by Cumulative Number of Annual Granted Patents
10.3.5. Analysis by Cumulative Number of Patent Applications
10.3.6. Analysis by Issuing Authority
10.3.7. Analysis by Type of Player
10.3.8. Analysis by Top Sections
10.3.9. Leading Industry Players: Analysis by Number of Patents
10.3.10. Leading Non-Industry Players: Analysis by Number of Patents
10.3.11. Leading Inventors: Analysis by Number of Patents
10.3.12. Non-Viral Drug Delivery Systems / Technologies: Patent Benchmarking Analysis

10.4. Analysis by Patent Valuation

11. PARTNERSHIPS AND COLLABORATIONS
11.1. Chapter Overview
11.2. Partnerships and Collaborations
11.3. Partnership Models

11.4. Non-Viral Drug Delivery Systems / Technologie: List of Partnerships and Collaborations
11.4.1. Analysis by Year of Partnership
11.4.2. Analysis by Type of Partnership
11.4.3. Analysis by Year and Type of Partnership
11.4.4. Analysis by Type of Partner
11.4.5. Analysis by Type of Molecule Delivered
11.4.6. Analysis by Type of Biologic Delivered
11.4.7. Analysis by Therapeutic Area
11.4.8. Most Active Players: Analysis by Number of Partnerships

11.4.9. Analysis by Geography
11.4.9.1. Local and International Agreements
11.4.9.2. Intracontinental and Intercontinental Agreements

12. OPPORTUNITY ASSESSMENT FRAMEWORK: KALBACH INNOVATION MODEL, COMPETITVE ASSESSMENT FRAMEWORK AND BCG MATRIX
12.1. Chapter Overview
12.2. Kalbach Innovation Model
12.2.1. Key Assumptions and Methodologies
12.2.2. Analysis by Trends in Research Activity
12.2.3. Analysis by Trends in Investment Activity
12.2.4. Analysis by Trends in Partnership Activity
12.2.5. Analysis by Number of Technologies
12.2.6. Analysis by Trends in Deal Amount
12.2.7. Analysis by Number of Google Hits
12.2.8. Qualitative and Quantitative Assessment based on Secondary and Primary Research
12.2.9. Kalbach Innovation Model: Analysis Output

12.3. Competitive Assessment Framework
12.3.1. Key Assumptions and Methodology
12.3.2. Competitive Assessment Framework: Analysis Output

12.4. BCG Matrix
12.4.1. Key Assumptions and Methodology
12.4.2. BCG Matrix: Output Analysis

SECTION VI: MARKET OPPORTUNITY ANALYSIS

13. GLOBAL NON-VIRAL DRUG DELIVERY SYSTEMS MARKET
13.1. Chapter Overview
13.2. Key Assumptions and Methodology

13.3. Global Non-Viral Drug Delivery Systems Market, Forecasted Estimates, Till 2035
13.3.1. Multivariate Scenario Analysis
13.3.1.1. Conservative Scenario
13.3.1.2. Optimistic Scenario

13.4. Key Market Segmentations

14. NON-VIRAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE OF MOLECULE DELIVERED
14.1. Chapter Overview
14.2. Key Assumptions and Methodology

14.3. Non-Viral Drug Delivery Systems Market: Distribution by Type of Molecule Delivered
14.3.1. Non-Viral Drug Delivery Systems Market for Biologics, Forecasted Estimates, Till 2035
14.3.2. Non-Viral Drug Delivery Systems Market for Small Molecules, Forecasted Estimates, Till 2035

14.4. Data Triangulation and Validation

15. NON-VIRAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE OF BIOLOGIC DELIVERED
15.1. Chapter Overview
15.2. Key Assumptions and Methodology

15.3. Non-Viral Drug Delivery Systems Market: Distribution by Type of Biologic Delivered
15.3.1. Non-Viral Drug Delivery Systems Market for RNA, Forecasted Estimates, Till 2035
15.3.2. Non-Viral Drug Delivery Systems Market for DNA, Forecasted Estimates, Till 2035
15.3.3. Non-Viral Drug Delivery Systems Market for Proteins / Peptides, Forecasted Estimates, Till 2035
15.3.4. Non-Viral Drug Delivery Systems Market for Antibodies, Forecasted Estimates, Till 2035

15.4. Data Triangulation and Validation

16. NON-VIRAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE OF VEHICLE USED
16.1. Chapter Overview
16.2. Key Assumptions and Methodology

16.3. Non-Viral Drug Delivery Systems Market: Distribution by Type of Vehicle Used
16.3.1. Non-Viral Drug Delivery Systems Market for Nanoparticles, Forecasted Estimates, Till 2035
16.3.2. Non-Viral Drug Delivery Systems Market for Extracellular Vesicles, Forecasted Estimates, Till 2035
16.3.3. Non-Viral Drug Delivery Systems Market for Polymers, Forecasted Estimates, Till 2035
16.3.4. Non-Viral Drug Delivery Systems Market for Oligonucleotides, Forecasted Estimates, Till 2035
16.3.5. Non-Viral Drug Delivery Systems Market for Cell Penetrating Peptides, Forecasted Estimates, Till 2035

16.4. Data Triangulation and Validation

17. NON-VIRAL DRUG DELIVERY SYSTEMS MARKET, BY TARGET THERAPEUTIC AREA
17.1. Chapter Overview
17.2. Key Assumptions and Methodology

17.3. Non-Viral Drug Delivery Systems Market: Distribution by Target Therapeutic Area
17.3.1. Non-Viral Drug Delivery Systems Market for Oncological Diseases, Forecasted Estimates, Till 2035
17.3.2. Non-Viral Drug Delivery Systems Market for Infectious Disorders, Forecasted Estimates, Till 2035
17.3.3. Non-Viral Drug Delivery Systems Market for Cardiovascular Disorders, Forecasted Estimates, Till 2035
17.3.4. Non-Viral Drug Delivery Systems Market for Genetic Diseases, Forecasted Estimates, Till 2035
17.3.5. Non-Viral Drug Delivery Systems Market for Hepatic Disorders, Forecasted Estimates, Till 2035
17.3.6. Non-Viral Drug Delivery Systems Market for Metabolic Disorders, Forecasted Estimates, Till 2035
17.3.7. Non-Viral Drug Delivery Systems Market for Neurological Disorders, Forecasted Estimates, Till 2035
17.3.8. Non-Viral Drug Delivery Systems Market for Pulmonary Disorders, Forecasted Estimates, Till 2035
17.3.9. Non-Viral Drug Delivery Systems Market for Rare Disorders, Forecasted Estimates, Till 2035
17.3.10. Non-Viral Drug Delivery Systems Market for Other Disorders, Forecasted Estimates, Till 2035

17.4. Data Triangulation and Validation

18. NON-VIRAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE OF PAYMENT EMPLOYED
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Revenue Shift Analysis

18.4. Non-Viral Drug Delivery Systems Market: Distribution by Type of Payment Employed
18.4.1. Non-Viral Drug Delivery Systems Market for Upfront Payments, Forecasted Estimates, Till 2035
18.4.2. Non-Viral Drug Delivery Systems Market for Milestone Payments, Forecasted Estimates, Till 2035

18.5. Data Triangulation and Validation

19. NON-VIRAL DRUG DELIVERY SYSTEMS MARKET, BY KEY GEOGRAPHICAL REGIONS
19.1. Chapter Overview
19.2. Key Assumptions and Methodology

19.3. Non-Viral Drug Delivery Systems Market: Distribution by Key Geographical Regions
19.3.1. Non-Viral Drug Delivery Systems Market in North America, Forecasted Estimates, Till 2035
19.3.2. Non-Viral Drug Delivery Systems Market in Europe, Forecasted Estimates, Till 2035
19.3.3. Non-Viral Drug Delivery Systems Market in Asia-Pacific, Forecasted Estimates, Till 2035

19.4. Penetration-Growth (P-G) Matrix

19.5. Data Triangulation and Validation

20. NON-VIRAL DRUG DELIVERY SYSTEMS MARKET, BY LEADING PLAYERS

SECTION VII: OTHER EXCLUSIVE INSIGHTS

21. CONCLUDING REMARKS

22. EXECUTIVE INSIGHTS
22.1. Chapter Overview
22.2. Small Company, Israel
22.2.1. Company Snapshot
22.2.2. Interview Transcript

22.3. Small Company, US
22.3.1. Company Snapshot
22.3.2. Interview Transcript

22.4. Small Company, France
22.4.1. Company Snapshot
22.4.2. Interview Transcript

22.5. Mid-sized Company, US
22.5.1. Company Snapshot
22.5.2. Interview Transcript

22.6. Small Company, Japan
22.6.1. Company Snapshot
22.6.2. Interview Transcript

22.7. Small Company, Switzerland
22.7.1. Company Snapshot
22.7.2. Interview Transcript

22.8. Small Company, Ireland
22.8.1. Company Snapshot
22.8.2. Interview Transcript

22.9. Small Company, Norway
22.9.1. Company Snapshot
22.9.2. Interview Transcript

22.10. Large Company, US
22.10.1. Company Snapshot
22.10.2. Interview Transcript

23. APPENDIX 1: TABULATED DATA

24. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Overall Systems / Technology Landscape
Figure 5.2 Executive Summary: Partnerships and Collaborations
Figure 5.3 Executive Summary: Market Sizing and Opportunity Analysis
Figure 6.1 Mechanism of Drug Transport Through Intestinal Epithelium
Figure 7.1 Non-Viral Drug Delivery Systems / Technologies: Distribution by Type of Molecule Delivered
Figure 7.2 Non-Viral Drug Delivery Systems / Technologies: Distribution by Type of Biologic Delivered
Figure 7.3 Non-Viral Drug Delivery Systems / Technologies: Distribution by Type of Drug Interaction
Figure 7.4 Non-Viral Intracellular Drug Delivery Systems: Distribution by Type of Vehicle Used
Figure 7.5 Most Active Players: Distribution by Number of Approved Drugs
Figure 7.6 Non-Viral Intracellular Drug Delivery Systems / Technology Providers: Distribution by Year of Establishment
Figure 7.7 Non-Viral Intracellular Drug Delivery Systems / Technology Providers: Distribution by Company Size
Figure 7.8 Non-Viral Intracellular Drug Delivery Systems / Technology Providers: Distribution by Location of Headquarters
Figure 7.9 Non-Viral Intracellular Drug Delivery Systems / Technology Providers: Distribution by Company Size and Location of Headquarters
Figure 7.10 Non-Viral Intracellular Drug Delivery Systems / Technology Providers: Distribution by Company Size and Type of Molecule Delivered
Figure 8.1 Technology Competitiveness Analysis: Non-Viral Drug Delivery Systems / Technology of Players based in North America (Peer Group Ia)
Figure 8.2 Technology Competitiveness Analysis: Non-Viral Drug Delivery Systems / Technology of Players based in North America (Peer Group Ib)
Figure 8.3 Technology Competitiveness Analysis: Non-Viral Drug Delivery Systems / Technology of Players based in Europe
Figure 8.4 Technology Competitiveness Analysis: Non-Viral Drug Delivery Systems / Technology of Players based in Asia-Pacific and Rest of the World
Figure 10.1 Patent Analysis: Distribution by Type of Patent
Figure 10.2 Patent Analysis: Distribution by Publication Year
Figure 10.3 Patent Analysis: Distribution by Application Year
Figure 10.4 Patent Analysis: Distribution by Cumulative Number of Granted Patents
Figure 10.5 Patent Analysis: Distribution by Cumulative Number of Patent Applications
Figure 10.6 Patent Analysis: Distribution by Issuing Authority / Patent Offices Involved
Figure 10.7 Patent Analysis: Distribution by Type of Player
Figure 10.8 Patent Analysis: Distribution by CPC Symbols
Figure 10.9 Leading Players: Distribution by Number of Patents
Figure 10.10 Leading Non-Industry Players: Distribution by Number of Patents
Figure 10.11 Leading Inventors: Distribution by Number of Patents
Figure 10.12 Non-Viral Drug Delivery Technologies: Patent Benchmarking Analysis
Figure 10.13 Non-Viral Drug Delivery Technologies: Patent Valuation Analysis
Figure 10.14 Patent Analysis: Leading Patents: Analysis by Number of Citations
Figure 11.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2020
Figure 11.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 11.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since 2020
Figure 11.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 11.5 Partnerships and Collaborations: Distribution by Type of Molecule Delivered
Figure 11.6 Partnerships and Collaborations: Distribution by Type of Biologic Delivered
Figure 11.7 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 11.8 Most Active Players: Distribution by Number of Partnerships
Figure 11.9 Partnerships and Collaborations: Distribution by Local and International Agreements
Figure 11.10 Partnerships and Collaborations: Distribution by Intracontinental and Intercontinental Agreements
Figure 12.1 Kalbach Innovation Model: Cumulative Year-wise Trend of Research Activity (In terms of Number of Publications)
Figure 12.2 Kalbach Innovation Model: Cumulative Trend by Number of Grants Awarded
Figure 12.3 Kalbach Innovation Model: Cumulative Trends in Partnership Activity
Figure 12.4 Kalbach Innovation Model: Distribution by Number of Technologies
Figure 12.5 Kalbach Innovation Model: Distribution by Amount of Deal
Figure 12.6 Kalbach Innovation Model: Distribution by Number of Google Hits
Figure 12.7 Kalbach Innovation Model: Spider Web Representation
Figure 12.8 Opportunity Assessment Framework: Kalbach Innovation Model
Figure 12.9 Opportunity Assessment Framework: Competitive Assessment Framework
Figure 12.10 Opportunity Assessment Framework: BCG Matrix
Figure 13.1 Licensing Agreements: Distribution of Financial Components
Figure 13.2 Licensing Agreements: Opportunity Estimation
Figure 13.3 Global Non-Viral Drug Delivery Systems / Technologies Market, Forecasted Estimates, Till 2035 (USD Billion)
Figure 13.4 Global Non-Viral Drug Delivery Systems / Technologies Market, Forecasted Estimates, Till 2035: Conservative Case (USD Billion)
Figure 13.5 Global Non-Viral Drug Delivery Systems / Technologies Market, Forecasted Estimates, Till 2035: Optimistic Case (USD Billion)
Figure 14.1 Non-Viral Drug Delivery Systems / Technologies Market: Distribution by Type of Molecule Delivered
Figure 14.2 Non-Viral Drug Delivery Systems / Technologies Market for Biologics, Forecasted Estimates, Till 2035 (USD Billion)
Figure 14.3 Non-Viral Drug Delivery Systems / Technologies Market for Small Molecules, Forecasted Estimates, Till 2035 (USD Billion)
Figure 15.1 Non-Viral Drug Delivery Systems / Technologies Market: Distribution by Type of Biologic Delivered
Figure 15.2 Non-Viral Drug Delivery Systems / Technologies Market for RNA, Forecasted Estimates, Till 2035 (USD Billion)
Figure 15.3 Non-Viral Drug Delivery Systems / Technologies Market for DNA, Forecasted Estimates, Till 2035 (USD Billion)
Figure 15.4 Non-Viral Drug Delivery Systems / Technologies Market for Proteins / Peptides, Forecasted Estimates, Till 2035 (USD Billion)
Figure 15.5 Non-Viral Drug Delivery Systems / Technologies Market for Antibodies, Forecasted Estimates, Till 2035 (USD Billion)
Figure 16.1 Non-Viral Drug Delivery Systems / Technologies Market: Distribution by Type of Vehicle Used
Figure 16.2 Non-Viral Drug Delivery Systems / Technologies Market for Nanoparticles, Forecasted Estimates, Till 2035 (USD Billion)
Figure 16.3 Non-Viral Drug Delivery Systems / Technologies Market for Extracellular Vehicles, Forecasted Estimates, Till 2035 (USD Billion)
Figure 16.4 Non-Viral Drug Delivery Systems / Technologies Market for Polymers, Forecasted Estimates, Till 2035 (USD Billion)
Figure 16.5 Non-Viral Drug Delivery Systems / Technologies Market for Oligonucleotides, Forecasted Estimates, Till 2035 (USD Billion)
Figure 16.6 Non-Viral Drug Delivery Systems / Technologies Market for Cell Penetrating Peptides, Forecasted Estimates, Till 2035 (USD Billion)
Figure 17.1 Non-Viral Drug Delivery Systems / Technologies Market: Distribution by Type of Target Therapeutic Area
Figure 17.2 Non-Viral Drug Delivery Systems / Technologies Market for Oncological Disorders, Forecasted Estimates, Till 2035 (USD Billion)
Figure 17.3 Non-Viral Drug Delivery Systems / Technologies Market for Infectious Diseases, Forecasted Estimates, Till 2035 (USD Billion)
Figure 17.4 Non-Viral Drug Delivery Systems / Technologies Market for Cardiovascular Disorders, Forecasted Estimates, Till 2035 (USD Billion)
Figure 17.5 Non-Viral Drug Delivery Systems / Technologies Market for Genetic Disorders, Forecasted Estimates, Till 2035 (USD Billion)
Figure 17.6 Non-Viral Drug Delivery Systems / Technologies Market for Hepatic Disorders, Forecasted Estimates, Till 2035 (USD Billion)
Figure 17.7 Non-Viral Drug Delivery Systems / Technologies Market for Metabolic Disorders, Forecasted Estimates, Till 2035 (USD Billion)
Figure 17.8 Non-Viral Drug Delivery Systems / Technologies Market for Neurological Disorders, Forecasted Estimates, Till 2035 (USD Billion)
Figure 17.9 Non-Viral Drug Delivery Systems / Technologies Market for Pulmonary Disorders, Forecasted Estimates, Till 2035 (USD Billion)
Figure 17.10 Non-Viral Drug Delivery Systems / Technologies Market for Rare Disorders, Forecasted Estimates, Till 2035 (USD Billion)
Figure 17.11 Non-Viral Drug Delivery Systems / Technologies Market for Other Disorders, Forecasted Estimates, Till 2035 (USD Billion)
Figure 18.1 Non-Viral Drug Delivery Systems / Technologies Market: Distribution by Type of Payment Employed
Figure 18.2 Non-Viral Drug Delivery Systems / Technologies Market for Upfront Payments, Forecasted Estimates, Till 2035 (USD Billion)
Figure 18.3 Non-Viral Drug Delivery Systems / Technologies Market for Milestone Payments, Forecasted Estimates, Till 2035 (USD Billion)
Figure 19.1 Non-Viral Drug Delivery Systems / Technologies Market: Distribution by Key Geographical Regions
Figure 19.2 Non-Viral Drug Delivery Systems / Technologies Market in North America, Forecasted Estimates, Till 2035 (USD Billion)
Figure 19.3 Non-Viral Drug Delivery Systems / Technologies Market in the US, Forecasted Estimates, Till 2035 (USD Billion)
Figure 19.4 Non-Viral Drug Delivery Systems / Technologies Market in Canada, Forecasted Estimates, Till 2035 (USD Billion)
Figure 19.5 Non-Viral Drug Delivery Systems / Technologies Market in Europe, Forecasted Estimates, Till 2035 (USD Billion)
Figure 19.6 Non-Viral Drug Delivery Systems / Technologies Market in the UK, Forecasted Estimates, Till 2035 (USD Billion)
Figure 19.7 Non-Viral Drug Delivery Systems / Technologies Market in Germany, Forecasted Estimates, Till 2035 (USD Billion)
Figure 19.8 Non-Viral Drug Delivery Systems / Technologies Market in Belgium, Forecasted Estimates, Till 2035 (USD Billion)
Figure 19.9 Non-Viral Drug Delivery Systems / Technologies Market in Ireland, Forecasted Estimates, Till 2035 (USD Billion)
Figure 19.10 Non-Viral Drug Delivery Systems / Technologies Market in Denmark, Forecasted Estimates, Till 2035 (USD Billion)
Figure 19.11 Non-Viral Drug Delivery Systems / Technologies Market in Rest of Europe, Forecasted Estimates, Till 2035 (USD Billion)
Figure 19.12 Non-Viral Drug Delivery Systems / Technologies Market in Asia-Pacific, Forecasted Estimates, Till 2035 (USD Billion)
Figure 19.13 Non-Viral Drug Delivery Systems / Technologies Market in South Korea, Forecasted Estimates, Till 2035 (USD Billion)
Figure 19.14 Non-Viral Drug Delivery Systems / Technologies Market in Australia, Forecasted Estimates, Till 2035 (USD Billion)
Figure 19.15 Non-Viral Drug Delivery Systems / Technologies Market in China, Forecasted Estimates, Till 2035 (USD Billion)
Figure 19.16 Penetration-Growth (P-G) Matrix: Key Geographical Regions
Figure 21.1 Concluding Remarks: Overall Systems / Technologies Landscape
Figure 21.2 Concluding Remarks: Patent Analysis
Figure 21.3 Concluding Remarks: Partnerships and Collaborations
Figure 21.4 Concluding Remarks: Market Forecast and Opportunity Analysis (I/II)
Figure 21.5 Concluding Remarks: Market Forecast and Opportunity Analysis (II/II)

List of Tables

Table 7.1 Non-Viral Drug Delivery Systems / Technologies: Information on Type of Molecule Delivered and Type of Biologic Delivered
Table 7.2 Non-Viral Drug Delivery Systems / Technologies: Information on Type of Interaction, Type of Vehicle Used and Number of Approved Drugs
Table 7.3 Non-Viral Drug Delivery Systems / Technologies: List of Providers
Table 9.1 Non-Viral Drug Delivery Systems / Technology Domain: List of Companies Profiled
Table 9.2 Arcturus Therapeutics: Company Overview
Table 9.3 Arcturus Therapeutics: Technology Portfolio
Table 9.4 Arcturus Therapeutics: Recent Developments and Future Outlook
Table 9.5 Bio-Path Holdings: Company Overview
Table 9.6 Bio-Path Holdings: Technology Portfolio
Table 9.7 Bio-Path Holdings: Recent Developments and Future Outlook
Table 9.8 CureVac: Company Overview
Table 9.9 CureVac: Technology Portfolio
Table 9.10 CureVac: Recent Developments and Future Outlook
Table 9.11 Entos Pharmaceuticals: Company Overview
Table 9.12 Entos Pharmaceuticals: Technology Portfolio
Table 9.13 Entos Pharmaceuticals: Recent Developments and Future Outlook
Table 9.14 etherna: Company Overview
Table 9.15 etherna: Technology Portfolio
Table 9.16 etherna: Recent Developments and Future Outlook
Table 9.17 Matinas Biopharma: Company Overview
Table 9.18 Matinas Biopharma: Technology Portfolio
Table 9.19 Matinas Biopharma: Recent Developments and Future Outlook
Table 9.20 MDimune: Company Overview
Table 9.21 MDimune: Technology Portfolio
Table 9.22 MDimune: Recent Developments and Future Outlook
Table 9.23 PCI Biotech: Company Overview
Table 9.24 PCI Biotech: Technology Portfolio
Table 9.25 PCI Biotech: Recent Developments and Future Outlook
Table 10.1 Patent Analysis: Top Sections
Table 10.2 Patent Analysis: Top Symbols
Table 10.3 Patent Analysis: Top Codes
Table 10.4 Patent Portfolio: Summary of Benchmarking Analysis
Table 10.5 Patent Analysis: Categorization Based on Weighted Valuation Score
Table 10.6 Patent Analysis: List of Relatively Higher Value Patents
Table 11.1 Non-Viral Drug Delivery Systems / Technologies: List of Partnerships and Collaborations, Since 2020
Table 11.2 Partnerships and Collaborations: Information on Type of Agreement
Table 13.1 Non-Viral Drug Delivery Systems / Technologies: Average Upfront and Milestone Payments, Since 2020 (USD Million)
Table 13.2 Leading Industry Players: Based on Number of Technology Licensing and Integration Deals
Table 13.3 Leading Industry Players: Based on Number of Partnership Deals
Table 23.1 Biond Biologics: Company Snapshot
Table 23.2 Carmine Therapeutics: Company Snapshot
Table 23.3 Eyevensys: Company Snapshot
Table 23.4 Generation Bio: Company Snapshot
Table 23.5 PCI Biotech: Company Snapshot
Table 23.6 SRI International: Company Snapshot
Table 24.1 Non-Viral Intracellular Drug Delivery Systems / Technologies: Distribution by Type of Molecule Delivered
Table 24.2 Non-Viral Intracellular Drug Delivery Systems / Technologies: Distribution by Type of Biologic Delivered
Table 24.3 Non-Viral Intracellular Drug Delivery Systems / Technologies: Distribution by Type of Drug Interaction
Table 24.4 Non-Viral Intracellular Drug Delivery Systems / Technologies: Distribution by Type of Vehicle Used
Table 24.5 Most Active Players: Distribution by Number of Approved Drugs
Table 24.6 Non-Viral Intracellular Drug Delivery Technology Providers: Distribution by Year of Establishment
Table 24.7 Non-Viral Intracellular Drug Delivery Technology Providers: Distribution by Company Size
Table 24.8 Non-Viral Intracellular Drug Delivery Technology Providers: Distribution by Location of Headquarters
Table 24.9 Non-Viral Intracellular Drug Delivery Technology Providers: Distribution by Company Size and Location of Headquarters
Table 24.10 Non-Viral Intracellular Drug Delivery Technology Providers: Distribution by Company Size and Type of Molecule Delivered
Table 24.11 Patent Analysis: Distribution by Type of Patent
Table 24.12 Patent Analysis: Distribution by Publication Year
Table 24.13 Patent Analysis: Distribution by Application Year
Table 24.14 Patent Analysis: Distribution by Cumulative Number of Granted Patents
Table 24.15 Patent Analysis: Distribution by Cumulative Number of Patent Applications
Table 24.16 Patent Analysis: Distribution by Issuing Authority
Table 24.17 Patent Analysis: Distribution by Cumulative Number of Patent Applications
Table 24.18 Leading Industry Players: Distribution by Number of Patents
Table 24.19 Leading Non-Industry Players: Distribution by Number of Patents
Table 24.20 Leading Inventors: Distribution by Number of Patents
Table 24.21 Patent Analysis: Distribution by Patent Age
Table 24.22 Non-Viral Drug Delivery Technologies: Patent Valuation Analysis
Table 24.23 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2020
Table 24.24 Partnerships and Collaborations: Distribution by Type of Partnership
Table 24.25 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since 2020
Table 24.26 Partnerships and Collaborations: Distribution by Type of Partner
Table 24.27 Partnerships and Collaborations: Distribution by Type of Molecule Delivered
Table 24.28 Partnerships and Collaborations: Distribution by Type of Biologic Delivered
Table 24.29 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 24.30 Most Active Players: Distribution by Number of Partnerships
Table 24.31 Partnerships and Collaborations: Distribution by Local and International Agreements
Table 24.32 Partnerships and Collaborations: Distribution by Intracontinental and Intercontinental Agreements
Table 24.33 Opportunity Assessment Framework: Kalbach Innovation Model
Table 24.34 Opportunity Assessment Framework: Competitive Assessment Model
Table 24.35 Opportunity Assessment Framework: BCG Matrix
Table 24.36 Global Non-Viral Drug Delivery Systems / Technologies Market, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.37 Global Non-Viral Drug Delivery Systems / Technologies Market, Forecasted Estimates, Till 2035: Conservative Case (USD Billion)
Table 24.38 Global Non-Viral Drug Delivery Systems / Technologies Market, Forecasted Estimates, Till 2035: Optimistic Case (USD Billion)
Table 24.39 Non-Viral Drug Delivery Systems / Technologies Market: Distribution by Type of Molecule Delivered
Table 24.40 Non-Viral Drug Delivery Systems / Technologies Market for Biologics, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.41 Non-Viral Drug Delivery Systems / Technologies Market for Small Molecules, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.42 Non-Viral Drug Delivery Systems / Technologies Market: Distribution by Type of Biologic Delivered
Table 24.43 Non-Viral Drug Delivery Systems / Technologies Market for RNA, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.44 Non-Viral Drug Delivery Systems / Technologies Market for DNA, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.45 Non-Viral Drug Delivery Systems / Technologies Market for Proteins / Peptides, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.46 Non-Viral Drug Delivery Systems / Technologies Market for Antibodies, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.47 Non-Viral Drug Delivery Systems / Technologies Market: Distribution by Type of Vehicle Used
Table 24.48 Non-Viral Drug Delivery Systems / Technologies Market for Nanoparticles, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.49 Non-Viral Drug Delivery Systems / Technologies Market for Extracellular Vehicles, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.50 Non-Viral Drug Delivery Systems / Technologies Market for Polymers, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.51 Non-Viral Drug Delivery Systems / Technologies Market for Oligonucleotides, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.52 Non-Viral Drug Delivery Systems / Technologies Market for Cell Penetrating Peptides, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.53 Non-Viral Drug Delivery Systems / Technologies Market: Distribution by Type of Target Therapeutic Area
Table 24.54 Non-Viral Drug Delivery Systems / Technologies Market for Oncological Disorders, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.55 Non-Viral Drug Delivery Systems / Technologies Market for Infectious Diseases, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.56 Non-Viral Drug Delivery Systems / Technologies Market for Cardiovascular Disorders, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.57 Non-Viral Drug Delivery Systems / Technologies Market for Genetic Disorders, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.58 Non-Viral Drug Delivery Systems / Technologies Market for Hepatic Disorders, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.59 Non-Viral Drug Delivery Systems / Technologies Market for Metabolic Disorders, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.60 Non-Viral Drug Delivery Systems / Technologies Market for Neurological Disorders, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.61 Non-Viral Drug Delivery Systems / Technologies Market for Pulmonary Disorders, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.62 Non-Viral Drug Delivery Systems / Technologies Market for Rare Disorders, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.63 Non-Viral Drug Delivery Systems / Technologies Market for Other Disorders, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.64 Non-Viral Drug Delivery Systems / Technologies Market: Distribution by Type of Payment Employed
Table 24.65 Non-Viral Drug Delivery Systems / Technologies Market for Upfront Payments, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.66 Non-Viral Drug Delivery Systems / Technologies Market for Milestone Payments, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.67 Non-Viral Drug Delivery Systems / Technologies Market: Distribution by Key Geographical Regions
Table 24.68 Non-Viral Drug Delivery Systems / Technologies Market in North America, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.69 Non-Viral Drug Delivery Systems / Technologies Market in the US, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.70 Non-Viral Drug Delivery Systems / Technologies Market in Canada, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.71 Non-Viral Drug Delivery Systems / Technologies Market n Europe, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.72 Non-Viral Drug Delivery Systems / Technologies Market in the UK, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.73 Non-Viral Drug Delivery Systems / Technologies Market in Germany, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.74 Non-Viral Drug Delivery Systems / Technologies Market in Belgium, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.75 Non-Viral Drug Delivery Systems / Technologies Market in Ireland, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.76 Non-Viral Drug Delivery Systems / Technologies Market in Denmark, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.77 Non-Viral Drug Delivery Systems / Technologies Market in Rest of Europe, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.78 Non-Viral Drug Delivery Systems / Technologies Market in Asia-Pacific, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.79 Non-Viral Drug Delivery Systems / Technologies Market in South Korea, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.80 Non-Viral Drug Delivery Systems / Technologies Market in Australia, Forecasted Estimates, Till 2035 (USD Billion)
Table 24.81 Non-Viral Drug Delivery Systems / Technologies Market in China, Forecasted Estimates, Till 2035 (USD Billion)

List of Companies